NewsSOS
Phase 3 results for clascoterone 5% topical solution, an investigational treatment for male androgenetic alopecia, are drawing attention across dermatology, according to a Globe Newswire release issued Monday.
Philip Werschler said the findings support a novel mechanism for the condition. What the data indicate Phase 3 marks the final required clinical testing stage before a drug sponsor can apply for regulatory approval.
Clascoterone 5% topical solution carries investigational status, the release confirms. Werschler's commentary centered on the mechanistic implications of the trial findings.
Specific enrollment figures, primary endpoints, and the sponsoring company were not identified in the available portion of the release.
Keep reading